Banu Karakus Yilmaz, Niyazi Ozüçelik Doğaç, Erdem Cevik, Dpekçi Afşin Doğan Hatice, Ozlem Uzun, Yasemin Celik, Afsin Ipekci
Bağcılar Research and Training Hospital, Emergency Department.
Bakirköy Dr. Sadi Konuk Research and Training Hospital, Emergency Department.
Afr Health Sci. 2014 Sep;14(3):757-62. doi: 10.4314/ahs.v14i3.36.
The aim of this study is testing the value of H-FABP in the early diagnosis of ACS alone or with routinely used biomarkers such as myoglobin, CK-MB, and cTn I in patients who admitted to emergency department (ED) with complaint of chest pain and suspected acute coronary syndrome.
This prospective and cross-sectional study was performed at the Emergency Department of University hospital between June 2009 and September 2010. Patients who were admitted with chest pain within first 48 hours and suspected ACS were enrolled to the study. Blood samples were taken for CK-MB, myoglobin, cTnI and H-FABP The patients were divided into two groups (ACS and non ACS). Statistical analyse were used for relation of biomarkers with diagnosis of ACS.
A 66 patients were included to the study. H-FAPB values were positive in 15.2% patients. When H-FABP was added to routinely used biomarkers in the diagnosis of ACS, increasing was observed in all sensitivity, specificity, PPV and NPV values. However, this increase was not statistically significant.
H-FABP did not provide any significant change in early diagnosis and exclusion of ACS diagnosis when used either alone or combination with routinely used biomarkers.
本研究旨在检测心脏型脂肪酸结合蛋白（H-FABP）在以胸痛为主诉并疑似急性冠状动脉综合征（ACS）而入住急诊科（ED）的患者中单独使用或与肌红蛋白、肌酸激酶同工酶（CK-MB）和肌钙蛋白I（cTnI）等常用生物标志物联合使用时对ACS早期诊断的价值。
本前瞻性横断面研究于2009年6月至2010年9月在大学医院急诊科进行。纳入在最初48小时内因胸痛入院且疑似ACS的患者。采集血液样本检测CK-MB、肌红蛋白、cTnI和H-FABP。将患者分为两组（ACS组和非ACS组）。采用统计学分析生物标志物与ACS诊断之间的关系。
66例患者纳入本研究。15.2%的患者H-FABP值呈阳性。在ACS诊断中，当将H-FABP添加到常用生物标志物中时，所有敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）均有升高。然而，这种升高无统计学意义。
H-FABP单独使用或与常用生物标志物联合使用时，在ACS的早期诊断及排除诊断方面均未产生任何显著变化。
